Expertise
Fabian Weykamp serves as Deputy Head of the Clinical Cooperation Unit (CCU) Radiotherapy at the German Cancer Research Center (DKFZ) and as Senior Physician in Radiation Oncology at Heidelberg University Hospital. He is the group leader of the Thoracic Radiotherapy and Radiation Oncology Representative at the Thoraxklinik Heidelberg.
His main areas of expertise are thoracic radiotherapy and MR-guided adaptive radiotherapy.
- Thoracic radiotherapy
- Online adaptive radiotherapy
- MR-guided radiotherapy
- Wei, C., Eze, C., Klaar, R., Thorwarth, D., Warda, C., Taugner, J., Hörner-Rieber, J., Regnery, S., Jaekel, O., Weykamp, F. and Palacios, M.A., 2025. Deep learning-based contour propagation in magnetic resonance imaging-guided radiotherapy of lung cancer patients. Physics in Medicine and Biology.
- Weykamp, F., Schaub, L., Eichhorn, M., Winter, H., Schirmacher, P., Thomas, M., Haberkorn, U., Ellerbrock, M., Adeberg, S., Debus, J. and Herfarth, K., 2024. Carbon Ion Beam Radiation Therapy as Part of a Trimodal Therapy for Non-small Cell Superior Sulcus Tumors: The INKA Study. Advances in radiation oncology, 9(9), p.101573.
- Fink, C.A., Weykamp, F., Adeberg, S., Bozorgmehr, F., Christopoulos, P., Lang, K., König, L., Hörner-Rieber, J., Thomas, M., Steins, M. and El-Shafie, R.A., 2023. Comorbidity in limited disease small-cell lung cancer: Age-adjusted Charlson comorbidity index and its association with overall survival following chemoradiotherapy. Clinical and Translational Radiation Oncology, 42, p.100665.
- Wiesweg, M., Küter, C., Schnorbach, J., Keyl, J., Metzenmacher, M., Cvetkovic, J., Saalfeld, F.C., Glanemann, F., Eberhardt, W., Oezkan, F. and Theegarten, D., 2025. Oligometastatic non‐small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome. International journal of cancer, 156(4), pp.776-787.
Jan-Henrik Bolten | Post-Doc | |||
Korneel Hartong | Researcher | |||
Lung Research - Projects
1. MARS (modular adaptive radiotherapy)
MR-guided radiotherapy offers decisive advantages for the treatment of lung cancer. The superior soft tissue contrast of MRI allows for more precise differentiation of tumours from adjacent structures, particularly in cases of atelectasis, which are often difficult to delineate on CT imaging. Diffusion-weighted imaging (DWI) provides additional functional information, enabling distinction between viable tumour tissue and scarred or collapsed lung. This makes MARS suitable for more accurate target volume definition, daily adaptation to anatomical changes, and improved sparing of organs at risk. As a result, lung cancer radiotherapy becomes not only more precise, but also safer and more effective.
2. PUMA and PUMA 2
The PUMA project is a multicenter DKTK feasibility study on MR-guided online adaptive radiotherapy in locally advanced NSCLC. In PUMA (Phase I), the aim is to demonstrate clinical feasibility: at each participating center, ten patients will undergo daily MR imaging (or CBCT with offline MRI); treatment plans will be adapted online weekly or in the event of major anatomical changes. Follow-up: 24 months, including assessment of toxicity, tumour control, and patient-reported outcomes. Complementary subprojects focus on AI-based dose accumulation, strategy comparisons, and early predictors, supported by a central database. The study is funded by the German Cancer Aid.
